). Viral vector is a critical component used in the manufacturing of CAR T cells, and third-generation lentiviral vectors offer improved safety over earlier generations1 I personally know someone that had a first generation CAR T after chemotherapy failed. To say that the side effect's were horrific is a big understatement. It really was terrible for that person, and many others I'm sure. These new 3rd generation CAR T's are addressing the safety of this type of treatment. The good thing for CHM, is that they are at the forefront of this 3rd generation treatment. Yes, this is the future of CAR T treatment, and we are in early with CHM. Paul Hopper is always looking for IP that is the future treatment, and he has done it again here. Adding to CHM other leading platform's we are heading in the right direction. CHM, grossly under valued, with this world class management team, that's got FDA approval for the first 4 out of 5 CAR T's in the world. CHM a major in the making, at a bargain price.
CHM Price at posting:
9.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)